within Pharmacolibrary.Drugs.ATC.C;

model C09AA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.44,
    Cl             = 0.7,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.096,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.028333333333333332,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Ramipril is an angiotensin-converting enzyme (ACE) inhibitor used primarily for the treatment of hypertension, heart failure, and to reduce the risk of cardiovascular events in high-risk patients. It is an approved and widely used antihypertensive medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li>S Meisel, A Shamiss, T Rosenthal,Clinical pharmacokinetics of ramipril.,Clinical pharmacokinetics,1994<a href='https://pubmed.ncbi.nlm.nih.gov/8137599/'>https://pubmed.ncbi.nlm.nih.gov/8137599/</a></li><li>Katja Čvan Trobec, Iztok Grabnar, Jurij Trontelj, Mitja Lainščak, Mojca Kerec Kos,Population pharmacokinetics of ramipril in patients with chronic heart failure: A real-world longitudinal study.,Acta pharmaceutica (Zagreb, Croatia),2024<a href='https://pubmed.ncbi.nlm.nih.gov/38815200/'>https://pubmed.ncbi.nlm.nih.gov/38815200/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09AA05;
